Exelixis Inc

-0.28 (-1.63%)
Products, Regulatory, Earnings Announcements

Exelixis, Ipsen Update On Cabozantinib

Published: 06/28/2021 05:13 GMT
Exelixis Inc (EXEL) - Exelixis and Ipsen Announce Cabozantinib in Combination With an Immune Checkpoint Inhibitor Significantly Improved Progression-free Survival in Phase 3 Cosmic-312 Pivotal Trial in Patients With Previously Untreated Advanced Liver Cancer.
Trial Will Continue As Planned to Final Analysis of Os; Results Are Anticipated in Early 2022.
Exelixis Plans to Discuss Trial Results and Next Steps for a Potential Regulatory Filing With U.S. Food and Drug Administration (fda).
Revenue is expected to be $299.31 Million
Adjusted EPS is expected to be $0.07

Next Quarter Revenue Guidance is expected to be $317.37 Million
Next Quarter EPS Guidance is expected to be $0.09

More details on our Analysts Page.